RTP Mobile Logo
Year in Review: On Demand — Significance and Relevance of Recent Data Sets and Publications in the Management of Lymphomas and Chronic Lymphocytic Leukemia
Released October 2018

Featuring key slides from the most important recent lymphoma presentations and publications and video interviews with Dr Bruce D Cheson, Dr Sonali M Smith and Dr Michael E Williams. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare professionals involved in the treatment of lymphomas and chronic lymphocytic leukemia (CLL).

    The treatment of hematologic cancers remains a challenge for many healthcare professionals and patients despite recent gains in the management of this group of diseases. Determining which treatment approach is most appropriate requires careful consideration of patient characteristics, physician expertise and available health-system resources. Published results from ongoing trials continually lead to the emergence of new therapeutic targets and regimens, thereby altering management algorithms. In order to offer optimal patient care, including the option of clinical trial participation, the practicing cancer clinician must be well informed of these advances.

    To bridge the gap between research and patient care, the Year in Review On Demand video program features one-on-one discussions with leading medical oncology investigators. By providing information on the latest, most important presentations and publications in the context of expert perspectives, this CME activity assists medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals with the formulation of current, evidence-based therapeutic strategies.


    • Determine the clinical relevance of recent research in the management of Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL) and CLL, as published in peer-reviewed journals and/or presented at major oncology conferences.
    • Recall published and emerging clinical research data in the formulation of therapeutic recommendations for patients with CLL, diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma.
    • Incorporate new therapeutic approaches into the best-practice management of newly diagnosed and relapsed/refractory HL.
    • Consider the mechanisms of action, efficacy and safety of approved and investigational immune checkpoint inhibitors for the treatment of HL and NHL, and determine the current or potential utility of these agents in clinical practice.
    • Appreciate available efficacy and safety data with chimeric antigen receptor T-cell therapy, and identify patients with relapsed/refractory B-cell lymphomas for whom this approach may be appropriate.
    • Assess the efficacy and safety of novel agents and approaches under investigation for HL, NHL and CLL.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of slide and video components.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Bruce D Cheson, MD
    Professor of Medicine
    Deputy Chief, Division of Hematology-Oncology
    Head of Hematology
    Georgetown University Hospital
    Lombardi Comprehensive Cancer Center
    Washington, DC

    Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, Gilead Sciences Inc, Pfizer Inc, Roche Laboratories Inc, Seattle Genetics, TG Therapeutics Inc; Consulting Agreement: Bayer HealthCare Pharmaceuticals; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, Gilead Sciences Inc, Roche Laboratories Inc, Seattle Genetics.

    Sonali M Smith, MD
    Elwood V Jensen Professor of Medicine
    Director, Lymphoma Program
    The University of Chicago
    Chicago, Illinois

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech, Gilead Sciences Inc, Kite Pharma Inc, Nordic Nanovector, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, Seattle Genetics; Contracted Research: Celgene Corporation.

    Michael E Williams, MD, ScM
    Byrd S Leavell Professor of Medicine
    Chief, Hematology/Oncology Division
    University of Virginia School of Medicine
    Charlottesville, Virginia

    Advisory Committee and Consulting Agreements: Celgene Corporation, Gilead Sciences Inc, Takeda Oncology, TG Therapeutics Inc; Contracted Research: Allos Therapeutics, Celgene Corporation, Gilead Sciences Inc, Novartis, TG Therapeutics Inc.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Acerta Pharma – A member of the AstraZeneca Group, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Kite Pharma Inc, Pharmacyclics LLC, an AbbVie Company, and Seattle Genetics.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: October 2018
    Expiration date: October 2019

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Chronic Lymphocytic Leukemia (CLL)

Follicular Lymphoma (FL)

Mantle Cell Lymphoma (MCL)

Diffuse Large B-Cell Lymphoma (DLBCL)

Hodgkin Lymphoma (HL)

Select Publications

Slide Presentation